<span item_type="fundamental" item_id="558e0084e3224d752b30c026b32a0038" counter_id="ST/US/COCHW" env="prod"></span><span item_type="announcement" item_id="511400964542761345" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 46 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.29.</p><p></p><h3>Financial Results for the Quarter Ended March 31, 2025</h3><h4>Segment Revenue</h4><ul><li>Net revenues decreased by $13 thousand for the three months ended March 31, 2025, compared to the same period in 2024, primarily due to a decrease in battery replacement sales caused by supply chain limitations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Cost of goods sold increased by $73 thousand, primarily due to increased headcount and new supplier expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>R&amp;D expenses increased by $400 thousand, driven by increased headcount and contractors in engineering and clinical departments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>Sales and marketing expenses rose by $33 thousand, mainly due to increased headcount and travel expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>General and administrative expenses decreased by $284 thousand, primarily due to reduced legal fees and professional service costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>Operating loss was - $5,107 thousand, compared to - $4,884 thousand in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>Net loss was - $4,998 thousand, compared to - $6,270 thousand in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was - $3,725 thousand, compared to - $5,589 thousand in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>Net cash used in investing activities was - $6 thousand, compared to - $109 thousand in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li><li>Net cash provided by financing activities was $3,554 thousand, compared to $6,426 thousand in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>Envoy Medical secured an additional $10 million in funding to advance its pivotal clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></li></ul><h4>Outlook / Guidance</h4><p>Envoy Medical is optimistic about the progress of its pivotal clinical study and anticipates that a significant percentage of cochlear implant candidates will prefer the fully implanted solution offered by the Acclaim cochlear implant. The company is focused on leveraging the natural anatomy of the ear for sound capture and improving patient quality of life.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea024047901ex99-1_envoy.htm"></span></p>

ENVOY MEDICAL INC C/WTS 29/09/2028 (TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 46 K